. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Eur J Nucl Med Mol Imaging. 2021 Jan 4;48(7):2259–2271. doi: 10.1007/s00259-020-05152-8

Table 1.

Patient characteristics (n = 351). Mean ± SD is indicated for continuous variables

	CN (n = 127)	MCI (n = 106)	AD_c (n = 84)	Non-AD (n = 34)	p value
Age	73.9 ± 6.8	71.7 ± 9.0	66.1 ± 9.2	65.3 ± 9.7	p ≤ .001^†
Sex (M, %)	45 (35%)	47 (44%)	44 (52%)	20 (59%)	p = .03
Education	14.9 ± 3.8	15.8 ± 3.0	15.5 ± 3.5	17.4 ± 4.2	p = .004^††
MMSE	29.2 ± 1.0	27.0 ± 2.7	20.9 ± 4.8	25.2 ± 6.3	p <.001^†††
Amyloid status (Aβ+, %)	48 (38%)	61 (58%)	81 (96%)	6 (18%)	p < .001
Provenance	UCSF ADRC 0	UCSF ADRC 15	UCSF ADRC 50	UCSF ADRC 33
	ADNI 80	ADNI 83	ADNI 16	ADNI 0
	BioFINDER 47	BioFINDER 8	BioFINDER 18	BioFINDER 1

CN cognitively normal, MCI mild cognitive impairment, AD_c Alzheimer’s disease dementia, non-AD_c non-AD disorders (including patients with clinical diagnoses of behavioral variant frontotemporal dementia, non-fluent variant primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and one subject with chronic traumatic encephalopathy)

^†

Significant for all pairwise comparisons except CN vs MCI (p = .26) and AD vs non-AD (p = 1.00)

^††

Pairwise comparisons significant only between CN and non-AD (p = .002)

^†††

Significant for all pairwise comparisons except MCI vs non-AD (p = 1.00)